Associations for Lipoprotein Lipase and Peroxisome Proliferator-activated Receptor-γ Gene and Coronary Artery Disease in an Indian Population

Archives of Medical Research

Volumn 41, Issue 1, 2010, Pages 19-25.e1

  AshokKumar, Manickaraj ^a   Veera Subhashini, Navaneethan Gnana ^a   Kanthimathi, Sekar ^a   SaiBabu, Ramineni ^a   Ramesh, Arabandi ^c   Cherian, Kotturathu Mammen ^a   Emmanuel, Cyril ^b  

^a International Centre for Cardio Thoracic and Vascular Diseases   (India)

^b Global Hospitals and Health City   (India)

^c UNIVERSITY OF MADRAS   (India)

Author keywords

Coronary artery disease; Indians; Lipoprotein lipase; Peroxisome proliferator activated receptor ; Polymorphisms; Type 2 diabetes

Indexed keywords

ALANINE; CREATININE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROLINE; SERINE; TRIACYLGLYCEROL;

ADULT; ALLELE; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; DISEASE SEVERITY; EXON; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; GENOTYPE; GLUCOSE BLOOD LEVEL; HETEROZYGOTE; HUMAN; INDIAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 77952315386     PISSN: 01884409     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcmed.2010.01.005     Document Type: Article

References (29)

1. Ezzati M., Vander Hoorn S., Rodgers A., et al. Estimates of global and regional potential health gains from reducing multiple major risk factors. Lancet 2003, 362:271-280.
2. Reddy K.S., Shah B., Varghese C., et al. Responding to the threat of chronic diseases in India. Lancet 2005, 366:1744-1749.
3. Lusis A.J., Mar R., Pajukanta P. Genetics of atherosclerosis. Annu Rev Genomics Hum Genet 2004, 5:189-218.
4. Grundy S.M., Benjamin I.J., Burke G.L., et al. Diabetes and cardiovascular disease. A statement for healthcare professionals from the American Heart Association. Circulation 1999, 100:1134-1146.
5. Blaschke F., Takata Y., Caglayan E., et al. Obesity, Peroxisome proliferator-activated receptor and atherosclerosis in type 2 diabetes. Arterioscler Thromb Vasc Biol 2006, 26:28-40.
6. Stein Y., Stein O. Lipoprotein lipase and atherosclerosis. Atherosclerosis 2003, 170:1-9.
7. Merkel M., Eckel R.H., Goldberg I.J. Lipoprotein lipase: genetics, lipid uptake, and regulation. J Lipid Res 2002, 43:1997-2006.
8. Lindi V.I., Uusitupa M.I.J., Lindström J., et al. Association of the Pro12Ala polymorphism in the PPAR-γ2 gene with 3-year incidence of type 2 diabetes and body weight change in the Finnish diabetes prevention study. Diabetes 2002, 51:2581-2586.
9. Doney A.S.F., Fischer B., Leese G., et al. Cardiovascular risk in type 2 diabetes is associated with variation at the PPARG locus: a Go-DARTS study. Arterioscler Thromb Vasc Biol 2004, 24:2403-2407.
10. Anderson J.L., King G.J., Bair T.L., et al. Association of lipoprotein lipase gene polymorphisms with coronary artery disease. J Am Coll Cardiol 1999, 33:1013-1020.
11. Radha V., Mohan V., Vidya R., et al. Association of lipoprotein lipase HindIII and Ser447Ter polymorphisms with dyslipidemia in Asian Indians. Am J Cardiol 2006, 97:1337-1342.
12. Humphries S.E., Nicaud V., Margalef J., et al. Lipoprotein lipase gene variation is associated with a paternal history of premature coronary artery disease and fasting and postprandial plasma triglycerides. The European Atherosclerosis Research Study (EARS). Arterioscler Thromb Vasc Biol 1998, 18:526-534.
13. Fajas L., Debril M.B., Auwerx J. Peroxisome proliferator-activated receptor-γ: from adipogenesis to carcinogenesis. J Mol Endocrinol 2001, 27:1-9.
14. Michalik L., Auwerx J., Berger J.P., et al. International union of pharmacology. LXI. Peroxisome proliferator activated receptors. Pharmacol Rev 2006, 58:726-741.
15. Doney A.S.F., Fischer B., Lee S.P., et al. Association of common variation in the PPARA gene with incident myocardial infarction in individuals with type 2 diabetes: a Go-DARTS study. Nucl Recep 2005, 3:4.
16. Knouff C., Auwerx J. Peroxisome proliferator-activated receptor-γ calls for activation in moderation: lessons from genetics and pharmacology. Endocr Rev 2004, 25:899-918.
17. Semple R.K., Chatterjee V.K.K., O'Rahilly S. PPARγ and human metabolic disease. J Clin Invest 2006, 116:581-589.
18. Nagy L., Szanto A. Roles for lipid-activated transcription factors in atherosclerosis. Mol Nutr Food Res 2005, 49:1072-1074.
19. Altshuler D., Hirschhorn J.N., Klannemark M., et al. The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 2000, 26:76-80.
20. Schneider J., Kreuzer J., Hamann A., et al. The proline 12 alanine substitution in the peroxisome proliferator-activated receptor-γ2 gene is associated with lower lipoprotein lipase activity in vivo. Diabetes 2002, 51:867-870.
21. Gerdes C., Gerdes L.U., Hansen P.S., et al. Polymorphisms in the lipoprotein lipase gene and their associations with plasma lipid concentrations in 40-year-old Danish men. Circulation 1995, 92:1765-1769.
22. 2, EDTA, storage time and temperature on DNA yield and quality. Biochem Genet 1993, 31:321-328.
23. Mori H., Ikegami H., Kawaguchi Y., et al. The Pro12→Ala substitution in PPAR-γ is associated with resistance to development of diabetes in the general population. Diabetes 2001, 50:891-894.
24. Kuivenhoven J.A., Groenemeyer B.E., Boer J.M.A., et al. Ser447stop mutation in lipoprotein lipase is associated with elevated HDL cholesterol levels in normolipidemic males. Arterioscl Thromb Vasc Biol 1997, 17:595-599.
25. Tai E.S., Corella D., Deurenberg-Yap M., et al. Differential effects of the C1431T and Pro12Ala PPARγ gene variants on plasma lipids and diabetes risk in an Asian population. J Lipid Res 2004, 45:674-685.
26. Radha V., Vimaleswaran K.S., Babu H.N.S., et al. Role of genetic polymorphism peroxisome proliferator-activated receptor-2 Pro12Ala on ethnic susceptibility to diabetes in South-Asian and Caucasian subjects. Diabetes Care 2006, 29:1046-1051.
27. Larson I., Hoffmann M.M., Ordovas J.M., et al. The lipoprotein lipase HindIII polymorphism: association with total cholesterol and LDL cholesterol, but not with HDL and triglycerides in 342 females. Clin Chem 1999, 45:963-968.
28. Holmer S.R., Hengstenberg C., Mayer B., et al. Lipoprotein lipase gene polymorphism, cholesterol subfractions and myocardial infarction in large samples of the general population. Cardiovas Res 2000, 47:806-812.
29. Reasner C.A. Reducing cardiovascular complications of type 2 diabetes by targeting multiple risk factors. J Cardiovasc Pharmacol 2008, 52:136-144.